版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
1、CarbohydratePolymers119(2015)219–227ContentslistsavailableatScienceDirectCarbohydratePolymersjournalhome page:www.elsevier.com/locate/carbpolOphiopogonpolysaccharideliposomecanenhancethenon-specific andspecificimmuneres
2、ponseinchickensYunpengFan a,1, XiaMa b,1, JingZhang c, LinMa a, YuanyuanGao a, WeiminZhang a, XiaopingSong a,?, WeifengHou a, ChaoGuo a, DewenTong a,?a CollegeofVeterinaryMedicine,NorthwestA OPL at highandmediu
3、mdoses could significantlyimprovethe phagocytosicindex, promotelymphocyteprolifera-tion,increasethe proportionof T lymphocytesubpopulations(CD4+ and CD8+), enhanceantibodytiterandimprovethe protectiverate in v
4、ivo.Moreover,its efficacy was significantlybetter thanophiopogonpolysaccharide(OP). Theseresultsindicatedthat the immune-enhancingactivityof OP wassignificantlyimprovedafter encapsulatedwith liposome.©201
5、4 ElsevierLtd. All rightsreserved.1.IntroductionAnimalepidemicshaveseriousandextensiveimpactonbreed-ingindustryinourcountry,whichforinstance,Newcastledisease,Avianinfluenza,porcinereproductiveandrespiratorysyndromeande
6、tc.oftenhappenandbringthebusinessagreatloss.Thesediseasesmostbelongtoviralinfectiousdiseases.Nowadays,vac-cinationisstilltheprincipalmeansforthepreventionandcontrolofviralinfectiousdiseasesowingtothelackofspecifictreatme
7、nt.However,mostvaccinesespeciallythegeneticallyengineeringvac-cinecangetsatisfactoryeffectwiththehelpofimmunopotentiator,whichplayanessentialroleinimprovingtheeffectofvaccine(ZhaoAbbreviations:OP,ophiopogonpolysaccharide
8、;OPL,ophiopogonpolysaccha-rideliposome;ND,Newcastledisease;IL,interleukin;PHA,phytohemagglutinin;MTT,3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide;PBS,phos-phatebufferedsaline;DMSO,dimethylsulfoxide;NDV,New
9、castlediseasevirus;VC,vaccinecontrol;BC,blankcontrol;BL,blankliposome;CC,cellcontrol. ? Correspondingauthorsat:CollegeofVeterinaryMedicine,NorthwestAfax:+00862987091032.E-mailaddress:dwtong@nwsuaf.edu.cn(D.Tong).1 Thesea
10、uthorscontributedequallytothiswork.etal.,2014).Whilethechemicalimmunopotentiatorweareusinginclinicpresentlyhavesomedisadvantagessuchaseasytocumu-late,singletarget,greatsideeffectsandsoon(Harandi,Medaglini,Shattock,Ma,Guo
11、,Wang,Hu,Zhangetal.,2013).Asanaturalmacromoleculeactivematerial,polysaccharidecannotonlyactivatetheimmunecells,improvethelevelofantibodies,promotethereleaseofcytokinesandactivatecomplement,butalsoplayimportantrolesinviru
12、scontrolandcancertherapy(Schepetkinetal.,2013;Sheu,Lyu,Lee,&Cheng,2013).Inaddition,polysaccharidewillnotproducesignif-icantsideeffectswhenitregulatestheimmunefunctionofbody,itistheidealimmunopotentiatorinclinicalappl
13、ication.Ophiopogonisjaponicus(RadixOphiopogonisJaponici),asatra-ditionalChinesemedicine,itsusecouldbedatedbackmorethan2000yearsagoandberecordedinShenNong’sMateriaMedica.http://dx.doi.org/10.1016/j.carbpol.2014.11.0480144
14、-8617/©2014ElsevierLtd.Allrightsreserved.Y.Fanetal./CarbohydratePolymers119(2015)219–2272212.4.2.ActivityofOPLonphagocytosisofmacrophagesinvitroThephagocytosisofmacrophageswasmeasuredbyneutralreduptake(Chen,Zhang,Sh
15、en,&Wang,2010).AfterculturedwithOPLorOPfor48h,100?Lofneutralredsolution(0.075%,w/w)wasaddedandincubatedfor4h.Afterdiscardingsupernatant,thecellswerewashedwithPBStwicetoremovetheneutralredwhichwasn’tphagocytizedbyMacr
16、ophages.ThenDMSO(100?Lwell?1)wasaddedtolyseMacrophages.Theabsorbanceat490nmwasassayedbyamicroplatereader.2.4.3.DeterminationofIL-2andIL-6levelsThemacrophageswereinoculatedinto96-wellcultureplates.Afterbeingtreatedwithorw
17、ithoutdrugsfor48h,theplateswerecentrifugedat1000×gfor10min,andthesupernatantwascol-lectedfordeterminingthecontentsofIL-2andIL-6byELISAkit(BiosamiteBiotechnologyCo.Ltd.Shanghai,China),respectively,accordingtothemanuf
18、acturer’sinstructions.2.4.4.ActivityofOPLonphagocyticindexinvivoThephagocyticindexofthemacrophageswasmeasuredbycar-bonclearanceaccordingtotheprocedureofpreviousdescription(Wang,Wang,Li,Shi,&Zhong,2009).Ninety14-day-o
19、ldchickenswererandomlyassignedintosixgroups.Thechickensinfiveexper-imentalgroupswereintramuscularlyinjectedwith1.0mL ofOPLathigh(4.0mg mL?1),medium(2.0mg mL?1)andlow(1.0mg mL?1)dose,OP(4.0mg mL?1)andBL,respectively,
20、inBCgroup,withphys-iologicalsaline,onceadayfor3successivedays.Ondays7and14afterthelastdrugadministration,sixchickenswerechosenran-domlyfromeachgroupandintravenouslyinjectedwithdilutedIndiainkat1mL/100gbodyweight.Bloodsam
21、pleswerecollectedat2min(T2)and10min(T10)fromthebrachialvein,andthen20?Lofbloodwasmixedwith2mL 0.1%Na2CO3.Theabsorbanceat600nmwasmeasuredonaUV–visiblespectrophotometer.Theliverandthespleenwereweighed,andthephagocyticinde
22、xwascalculatedasfollows:K=(lgOD2 ?lgOD10)/(T10 ?T2).Phagocyticindex=K1/3 ×Mbodyweight/(Mliverweight +Mspleenweight).2.5.ActivityofOPLonspecificimmuneresponseThreehundred14-day-oldchickenswererandomlydividedintoseven
23、groupsandvaccinatedwithNDvaccine(LaSotastrain,no.130920,Bio-drugCompanyofVeterinary,BeijingCity)exceptBCgroup,repeatedvaccinationat28-day-old.Atthesametimeofthefirstvaccination,thechickensinfiveexperimentalgroupswereintr
24、amuscularlyinjectedwith1.0mL ofOPLathigh(4.0mg mL?1),medium(2.0mg mL?1)andlow(1.0mg mL?1)dose,OP(4.0mgmL?1)andBL,respectively,invaccinecontrol(VC)andBCgroups,1.0mL ofphysiologicalsaline.Ondays7,14,21,28and35afterthe
25、firstvaccination,thebloodsamplesofsixchickenswerecollectedrandomlyfromeachgroupformeasuringperiph-erallymphocyteproliferationbyMTTmethod,CD4+ andCD8+ Tcellsdistributionbyflowcytometry,andserumhemagglutina-tioninhibition(
26、HI)antibodytiterbymicro-method.Onday35afterthefirstvaccination,thechickensexceptforBCgroupwerechallengedwith0.5mL ofNDV(F48E9strain,suppliedbyChinainstituteofveterinarydrugcontrol)with10LD50 byintramuscularinjection.The
27、pathogenicanddeadstatusesofchickenswereexam-ineddailyfor15successivedaysafterchallenged.Themortality,morbidityandprotectiverateineachgroupwascalculatedaccord-ingtotheformula:mortality(%)=thenumberofdeadchickenuptoday15af
28、terchallenge(D15)/thenumberofsample×100%,morbidity(%)=thenumberofchickensdeadandshowingclinicalsymptomsonD15/thenumberofsample×100%,protectiverate(%)=thenumberofchickenswithoutclinicalsymptomsonD15/thenumberofs
29、ample×100%.2.6.LymphocytesproliferationassayLymphocytesproliferationwasperformedaspreviouslydescribed(Zhaoetal.,2011).Briefly,bloodsampleswerecollectedfromheart,andthencarefullylayeredonthesurfaceoflymphocyteseparat
30、ionmedium.Aftercentrifugated,lymphocyteswerecol-lectedandwashedtwicewithRPMI-1640.Thenweredilutedinto2.5×106 mL?1 andaddedinto96-wellplateswith80?Lwell?1,another20?LofPHAwasadded.Theplateswereincubatedinahumidatmosp
31、hereof5%CO2 at37.5 ?C.Afteraculturefor44h,20?LofMTT(5?gmL?1)wasadded,andtheplateswerere-incubatedfor4h.Thenthesupernatantwasremovedand100?LofDMSOwereaddedandshakenfor5min.Theabsorbanceat570nm(A570 value)wasmeasuredasthei
32、ndexofperipheralTlymphocytesproliferation.2.7.SerumHIantibodyassayBloodsamplewerecollected,putintoEppendorftubesandallowedtoclotat37 ?Cfor2h.SerumwasseparatedandinactivatedcomplementsforassayingHIantibody.Themethodwasref
33、erredtothepreviousreport(Zhaoetal.,2011).Themeantiterwasexpressedasreciprocallog2 valuesofthehighestdilutionthatdisplayedHI.2.8.MeasurementofCD4+ andCD8+ TcellsTlymphocyteswerecollectedaccordingtothemethodin2.5.Then50?Lo
34、flymphocyteswereaddedtoFalcontubes.Afteradded2?Lofmonoclonalantibodies(anti-CD4+-FITCandanti-CD8+-PE),themixturewasincubatedinthedarkat4 ?Cfor30min.Aftercen-trifugation(2000×g,at4 ?Cfor5min),thecellswerewashedwithPB
35、S,andresuspendedin0.5mLofPBS.ThepercentagesofCD4+ andCD8+ Tcellsweremeasuredbyflowcytometry(Yang,Chen,Sun,Ye,&Fang,2007).2.9.StatisticalanalysisDataareexpressedasthemean±S.D.Duncan’smultiplerangetestwasusedtodet
36、erminethedifferencesamonggroupswiththesoftwareSPSS19.0.?2-Testwasusedtoanalyzethedifferenceofthemortality,morbidityandprotectiverate.SignificantdifferenceswereconsideredasP<0.05.3.Results3.1.Non-specificimmuneresponse
37、experiment3.1.1.TheeffectofOPLonphagocytosisofmacrophagesTheeffectofOPLonphagocytosisofneutralredisillustratedinFig.1.At125–7.813?gmL?1,theA490 valuesinOPLandOPgroupsweresignificantlyhigherthanthoseinBLandCCgroup(P<0.
38、05).TheA490 valuesinOPLat125,31.25and7.813?gmL?1 groupsweresignificantlyhigherthanthoseinallOPgroups(P<0.05).3.1.2.TheeffectofOPLonIL-2secretionTheeffectofOPLonthereleaseofIL-2frommecrophagesisshowninFig.2.TheIL-2conc
39、entrationsinOPLat125–15.625?gmL?1 andOPat125–31.25?gmL?1 groupsweresignificantlyhigherthanthoseinBLandCCgroups(P<0.05).TheIL-6concentrationsinOPLweresignificantlyhigherthanthoseinOPat125–31.25?gmL?1 groups(P<0.05).
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 眾賞文庫(kù)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 外文翻譯--麥冬多糖脂質(zhì)體可以提高雞的非特異性和特異性免疫應(yīng)答
- 外文翻譯--麥冬多糖脂質(zhì)體可以提高雞的非特異性和特異性免疫應(yīng)答
- 外文翻譯--麥冬多糖脂質(zhì)體可以提高雞的非特異性和特異性免疫應(yīng)答(英文).pdf
- 外文翻譯--麥冬多糖脂質(zhì)體可以提高雞的非特異性和特異性免疫應(yīng)答(英文).pdf
- 外文翻譯--麥冬多糖脂質(zhì)體可以提高雞的非特異性和特異性免疫應(yīng)答(譯文)
- 外文翻譯--麥冬多糖脂質(zhì)體可以提高雞的非特異性和特異性免疫應(yīng)答(譯文).doc
- 外文翻譯--麥冬多糖脂質(zhì)體可以提高雞的非特異性和特異性免疫應(yīng)答(譯文).doc
- 非特異性免疫和特異性免疫復(fù)習(xí)
- 非特異性免疫
- 特異性腰痛與非特異性腰痛的對(duì)比研究.pdf
- 西施舌非特異性免疫研究.pdf
- 分?jǐn)?shù)和小數(shù)數(shù)量表征的符號(hào)特異性和非特異性
- 分?jǐn)?shù)和小數(shù)數(shù)量表征的符號(hào)特異性和非特異性.pdf
- 魚類非特異性免疫研究概況【文獻(xiàn)綜述】
- 九孔鮑非特異性免疫研究.pdf
- 非特異性感染病人的護(hù)理
- 人源性α-防御素對(duì)脂質(zhì)體膜非特異性靶向作用的研究.pdf
- 浙貝母病害的檢測(cè)和茯苓多糖對(duì)鱉非特異性免疫的作用.pdf
- 非特異性脊柱感染誤診的臨床分析.pdf
- 應(yīng)激對(duì)黃顙魚非特異性免疫細(xì)胞的影響.pdf
評(píng)論
0/150
提交評(píng)論